Enrollment in High-Deductible Health Plans and Its Impact on Buprenorphine Access
Overview
This study evaluates the impact of switching to high-deductible health plans (HDHPs) on buprenorphine dispensing and opioid use disorder (OUD)-related healthcare visits among privately insured adults. Findings indicate that switching to an HDHP does not significantly alter buprenorphine dispensing or OUD-related outpatient visits, although the effects on emergency department visits and hospitalizations require further investigation.
Background
Buprenorphine is a critical medication for reducing opioid-related mortality among patients with opioid use disorder (OUD). Despite its benefits, treatment access remains limited, with only 20% of individuals with OUD receiving appropriate medication. The increasing prevalence of high-deductible health plans (HDHPs) raises concerns about potential barriers to accessing essential treatments like buprenorphine, which could exacerbate the ongoing opioid crisis.
Data Highlights
No significant changes in buprenorphine dispensing or OUD-related outpatient visits were observed among patients switching to HDHPs.
Key Findings
42% of privately insured US residents under 65 were enrolled in HDHPs in 2023.
Switching to an HDHP was not associated with changes in buprenorphine dispensing among patients with pre-existing use.
No significant increase in OUD-related outpatient visits was noted after switching to an HDHP.
The study analyzed data from the Optum Labs Data Warehouse, covering claims from over 300 million enrollees.
Further research is needed to assess the impact of HDHPs on emergency department visits and hospitalizations related to OUD.
Clinical Implications
Clinicians should be aware that switching to high-deductible health plans may not directly affect buprenorphine access or outpatient care for patients with OUD. However, ongoing monitoring of healthcare utilization patterns is essential to identify any emerging barriers to treatment.
Conclusion
The findings suggest that the transition to high-deductible health plans does not significantly impact buprenorphine dispensing or outpatient visits for OUD, but further research is warranted to explore potential effects on emergency care and hospitalizations.
A year-long LC-MS/MS study suggests wastewater surveillance can reveal shifts in drug consumption linked to public events, weekends, and law enforcement activity
